Kirkland Advises Trilantic-Backed SOFIE Biosciences on Acquisition by GE HealthCare

Kirkland & Ellis advised Trilantic-backed SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, on a definitive agreement to be acquired by GE HealthCare (Nasdaq: GEHC) for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment. The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical "final mile" of U.S. PET radiopharmaceutical supply.

Read the transaction press release

The Kirkland team included corporate lawyers Shawn OHargan and Philippe Simard; technology & IP transactions lawyer Joanna Schlingbaum; healthcare transactions lawyer Lindsay Borgeson; and tax lawyers Vincent Thorn and Liam Murphy.